Tharimmune, Inc., was incorporated as a Delaware corporation on March 28, 2017. The company is a preclinical biotechnology company developing novel therapeutic candidates for iron death, an emerging anti-cancer mechanism that leads to IMCD for the treatment of drug-resistant cancers. The most advanced product candidate they have is HSB-1216, an IMCD inducer that targets a variety of solid tumors. The company uses its proprietary tumor targeting platform Quatrame to enhance the absorption of HSB-1216 in TME, prolong the duration of action and minimize off-target toxicity. In addition, their artificial intelligence precision medicine platform Trident is used to identify biomarkers in clinical programs to target specific patient groups. 

THAR

THAR Profile